pumpsci

GLP-1, originally developed for diabetes, has demonstrated significant benefits, including reductions in obesity and evidence suggesting decreased risks of heart disease, kidney disease, Parkinson’s, and Alzheimer’s. Scoring 10 out of 12 on the gerotherapeutic scale, it effectively targets key mechanisms of aging, highlighting its potential for broader therapeutic applications.